- Home
- MIRA vs CURX Comparison
MIRA vs CURX Comparison
Compare MIRA & CURX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRA
- CURX
- Stock Information
- Founded
- MIRA 2020
- CURX 2018
- Country
- MIRA United States
- CURX United States
- Employees
- MIRA N/A
- CURX N/A
- Industry
- MIRA Biotechnology: Pharmaceutical Preparations
- CURX Biotechnology: Pharmaceutical Preparations
- Sector
- MIRA Health Care
- CURX Health Care
- Exchange
- MIRA Nasdaq
- CURX Nasdaq
- Market Cap
- MIRA 33.7M
- CURX 29.7M
- IPO Year
- MIRA 2023
- CURX 2025
- Fundamental
- Price
- MIRA $1.67
- CURX $0.68
- Analyst Decision
- MIRA
- CURX
- Analyst Count
- MIRA 0
- CURX 0
- Target Price
- MIRA N/A
- CURX N/A
- AVG Volume (30 Days)
- MIRA 8.9M
- CURX 2.7M
- Earning Date
- MIRA 11-14-2025
- CURX 09-09-2025
- Dividend Yield
- MIRA N/A
- CURX N/A
- EPS Growth
- MIRA N/A
- CURX N/A
- EPS
- MIRA N/A
- CURX N/A
- Revenue
- MIRA N/A
- CURX N/A
- Revenue This Year
- MIRA N/A
- CURX N/A
- Revenue Next Year
- MIRA N/A
- CURX N/A
- P/E Ratio
- MIRA N/A
- CURX N/A
- Revenue Growth
- MIRA N/A
- CURX N/A
- 52 Week Low
- MIRA $0.73
- CURX $3.61
- 52 Week High
- MIRA $2.45
- CURX $8.60
- Technical
- Relative Strength Index (RSI)
- MIRA 60.28
- CURX N/A
- Support Level
- MIRA $1.57
- CURX N/A
- Resistance Level
- MIRA $1.80
- CURX N/A
- Average True Range (ATR)
- MIRA 0.18
- CURX 0.00
- MACD
- MIRA 0.02
- CURX 0.00
- Stochastic Oscillator
- MIRA 35.00
- CURX 0.00
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
About CURX Curanex Pharmaceuticals Inc Common Stock
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout.